Wilson Therapeutics AB (publ) Interim Report January 1 – September 30, 2016
Clinical trial on track, final results expected before year-end.July 1 – September 30, 2016 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 31.9 M (loss: 18.6) · Loss per share, before and after dilution, totaled SEK 1.24 (loss: 14.61) · At September 30, cash and cash equivalents amounted to SEK 415.6 M (9.9) January 1 – September 30, 2016 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 81.1 M (loss: 49.1) · Loss per share, before and after dilution, totaled SEK 5.81 (loss: 38.69) Significant events during the period